Thursday, June 09, 2011 12:29:34 PM
Sign me up as a test subject...
'Super Breed' Of Medicinal Cannabis Developed By British Drug Firm
Updated: Thursday, 09 Jun 2011, 11:40 AM EDT
Published : Wednesday, 08 Jun 2011, 6:55 AM EDT
By NewsCore
A five bladed leaf from a three month old female cannabis sativa plant.
LONDON - A British pharmaceutical company was working Wednesday to develop a new breed of cannabis-based products aimed at treating a range of conditions including diabetes, epilepsy and Crohn's disease.
GW Pharmaceuticals, which launched a cannabis-derived medicine for symptoms of multiple sclerosis last year, has cross-bred different types of the plant to produce a new strain that could treat a wide range of disorders.
The new varieties contain enhanced levels of therapeutic compounds, including an appetite suppressant cannabinoid called THCV, which the company hopes will be used in the treatment of type 2 diabetes, obesity and other metabolic disorders.
Research leader Dr. David Potter said, "We've demonstrated that there are something like 60 cannabinoids in the cannabis plant, and so far we've looked in detail only at 12 to 15. You could say we've only scratched the surface so far."
Human safety trials are already underway on some of the new varieties, and the company hopes that by combining THCV with other cannabinoids they will be able to treat inflammatory diseases and epilepsy.
Read more: http://www.myfoxdc.com/dpp/news/offbeat/super-breed-of-medicinal-cannabis-developed-by-british-drug-firm-ncxdc-060811#ixzz1OnTDmYfj
'Super Breed' Of Medicinal Cannabis Developed By British Drug Firm
Updated: Thursday, 09 Jun 2011, 11:40 AM EDT
Published : Wednesday, 08 Jun 2011, 6:55 AM EDT
By NewsCore
A five bladed leaf from a three month old female cannabis sativa plant.
LONDON - A British pharmaceutical company was working Wednesday to develop a new breed of cannabis-based products aimed at treating a range of conditions including diabetes, epilepsy and Crohn's disease.
GW Pharmaceuticals, which launched a cannabis-derived medicine for symptoms of multiple sclerosis last year, has cross-bred different types of the plant to produce a new strain that could treat a wide range of disorders.
The new varieties contain enhanced levels of therapeutic compounds, including an appetite suppressant cannabinoid called THCV, which the company hopes will be used in the treatment of type 2 diabetes, obesity and other metabolic disorders.
Research leader Dr. David Potter said, "We've demonstrated that there are something like 60 cannabinoids in the cannabis plant, and so far we've looked in detail only at 12 to 15. You could say we've only scratched the surface so far."
Human safety trials are already underway on some of the new varieties, and the company hopes that by combining THCV with other cannabinoids they will be able to treat inflammatory diseases and epilepsy.
Read more: http://www.myfoxdc.com/dpp/news/offbeat/super-breed-of-medicinal-cannabis-developed-by-british-drug-firm-ncxdc-060811#ixzz1OnTDmYfj
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
